Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HP501 Sustained-release Tablets in Hyperuricemia (Phase II)
CTR20201456Phase 2Completed
- Sponsor
- Hinova Pharmaceuticals Inc.
- Start
- Aug 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of HP501 in hyperuricemia, gout, sponsored by Hinova Pharmaceuticals Inc.. Started Aug 2020; status: completed.
02
Drugs
HP501
03
Conditions
hyperuricemiagout
Beyond the preview
Go deeper on CTR20201456.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20201456.